NEW YORK (TheStreet) -- Genocea Biosciences (GNCA) - Get Report stock is up by 26.20% to $5.01 on heavy trading volume on Thursday morning, after the company reported positive efficacy data from a Phase 2 trial for its genital herpes treatment.
The biopharmaceutical company announced on Thursday that its drug, GEN-003, showed "sustained and statistically significant reductions" in viral shedding a year after treatment. Viral shedding potentially causes the spread of genital herpes, the company said in a statement.
Genital herpes is a common sexually transmitted disease in the U.S., according to the Centers for Disease Control and Prevention.
"A single course of treatment of GEN-003 may offer benefits similar to a full year of daily administration of oral antivirals - but with greatly improved convenience," CEO Chip Clark added in a statement.
So far today, 3.78 million shares of Genocea have traded, well above the company's 30-day average of about 128,000 shares.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself.
You can view the full analysis from the report here: GNCA